Market Overview

The global market for Lung Cancer Diagnostics is projected to reach US$3.2 billion by 2025

Share:

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- The global market for Lung Cancer Diagnostics is projected to reach US$3.2 billion by 2025, driven by rising incidence and growing economic burden of lung cancer in terms of survival rates and medical expenditure. Rising environmental pollution is taking its toll on the health of the population. Among the many factors attributed to the epidemic spread of cancer is the rising air pollution as evidenced by unchecked presence of particulate matter (PM10 and PM2.5) in outdoor and indoor air. Increase in the cacogenic load in the environment is catalyzing the prevalence of all types of cancers. Exposure to particulate matter (PM2.5) in the air as a result of deteriorating air quality in global cities is a key reason amplifying the incidence and prevalence of lung cancer. Thousands of cities today have air pollution significantly higher than the safe levels established by WHO, exposing billions of people around the world to dangerous air. Over 8.5 million deaths occur each year due to exposure to fine particles in polluted air, with lung cancer leading the mortality rate.



Read the full report: https://www.reportlinker.com/p05834219/?utm_source=PRN



Against the backdrop of the emerging picture of disease severity, there is growing focus shed on early detection, diagnosis and supportive treatment. Given that any cancer when detected at an early stage before it has spread has a higher likelihood of being successfully treated, there is strong focus shed on lung cancer screening. Screening provides new hope for early detection and more successful treatment of lung cancer. As compared to other cancers, survival rates associated with lung cancer is low and the disease is often identified only at advanced stages since symptoms closely mimic those associated with infections, emphysema, COPD and smoking thereby leading to misdiagnosis. Currently gaining significance is a low-dose CAT scan (LDCT) with research studies proving the diagnostic technique to be effective in identifying abnormal lesions in the lungs in high risk patients. Also a growth driver is the expanding base of high risk population which includes aging people in the 60+ age group, growing number of smokers, rise in COPD which is a major risk factor for cancer and premature lung aging.

A key sector of the market poised to witness above average growth is the emerging field of liquid biopsies. Until recently, testing for mutations was carried out only by tissue-biopsy-based testing which is ridden with challenges and clinical inefficiency. Tissue biopsies are effective in confirming a diagnosis and identifying corresponding molecular abnormalities. However, the test does not offer the in-depth understanding of the tumor which is required for timely and effective treatment. Liquid biopsy, on the other hand, enhances the effectiveness of the treatment of NSCLC, with the ability to circumvent all the biological limitations of tissue biopsy. A key of benefit of liquid biopsies will however be a reduction in the number of unrequired and unnecessary tissue biopsies. This is a significant advantage especially in the current era of value based care which aims to reduce healthcare wastages. The benefit in healthcare cost savings can be put into perspective by the fact that in the United States in the breast cancer sector alone over 1.5 million breast tissue biopsies are performed annually with only 25% of these tests resulting in a confirmatory cancer diagnosis. Liquid biopsies given their ability provide greater diagnostic insights can help close the wastages involved in cancer diagnosis. The United States and Europe represent large markets worldwide with a combined share of 49.3% of the global market. China ranks as the fastest growing market with a CAGR of 11.4% over the analysis period supported by rising incidence of lung cancer as a result of diversity in lifestyles and socioeconomic development including occupational factors.



Read the full report: https://www.reportlinker.com/p05834219/?utm_source=PRN

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Early Detection of Lung Cancer Takes Precedence, Driving the
Demand for Lung Cancer Diagnostics
Non-small Cell Lung Cancer - The More Prominent of the Two Lung
Cancer Types
Imaging Tests Segment Dominates the Market, Molecular Tests
Category to Witness High Growth
US Leads the Lung Cancer Diagnostics Market, Asia-Pacific to
Witness Fastest Growth
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS
Agilent Technologies Inc. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Illumina, Inc. (USA)
NeoGenomics Laboratories, Inc. (USA)
QIAGEN N.V. (The Netherlands)
Thermo Fisher Scientific, Inc. (USA)
Veracyte (USA)

3. MARKET TRENDS & DRIVERS
Increasing Prevalence and Incidence of Lung Cancer to Push the
Demand for Early Diagnoses
Age-Standardized Lung Cancer Rates for Select Countries
Age-Standardized Lung Cancer Rates in Men for Select Countries
Age Standardized Lung Cancer Rates in Women for Select Countries
Lung Cancer-Specific Biomarkers to Spur Market Growth
Select Lung Cancer Biomarkers
New Potential Biomarker for Early Stage Lung Cancer Identified
in a Recent NCI Study (2019)
Advancements and Research Initiatives in Lung Cancer
Diagnostics Space
EFIRM Test for Detection of Lung Cancer-related EGFR Mutations
in NSCLC Patients
A Glance at Select Recent Launches of Lung Cancer Diagnostic Tests
New Product Launches/Approvals in the Lung Cancer Diagnostics
Recent Approvals
Liquid Biopsies Grow in Value as a Diagnostic Tool Supporting
Therapy Decisions in NSCLCs
Effervescent Rate of New Innovations & Product Development Will
Make Liquid Biopsy a Readily Available Option for Patients in
the Coming Years
High Cigarette Consumption/Rise in Prevalence of Smoking
Increases the Incidence of Lung Cancer
Cigarette Consumption Per Year Per Person Across Select
Countries: 2016
Top 15 Countries with the Highest Smoking Rates: 2015
Increasing Number of Awareness Programs for Lung Cancer and
Symptoms
Growing Availability of Government/Private Funding for R&D to
Develop Lung Cancer Diagnostics
National Cancer Institute Research Funding for Lung Cancer in
US$ Million for the Years 2014 through 2017
Aging Demographics & Unhealthy Lifestyles Raise the Risk of Cancer
Cancer Prone Sites based on Age
Global Population Statistics for the 65+ Age Group in Million
by Geographic Region for the Years 2019, 2025, 2035 and 2050

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Lung Cancer
Diagnostics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027

Table 2: World Historic Review for Lung Cancer Diagnostics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019

Table 3: World 15-Year Perspective for Lung Cancer Diagnostics
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Imaging Tests by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027

Table 5: World Historic Review for Imaging Tests by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 6: World 15-Year Perspective for Imaging Tests by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Sputum Cytology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027

Table 8: World Historic Review for Sputum Cytology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019

Table 9: World 15-Year Perspective for Sputum Cytology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Molecular Tests
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027

Table 11: World Historic Review for Molecular Tests by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019

Table 12: World 15-Year Perspective for Molecular Tests by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Biopsy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027

Table 14: World Historic Review for Biopsy by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 15: World 15-Year Perspective for Biopsy by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Other Tests by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027

Table 17: World Historic Review for Other Tests by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 18: World 15-Year Perspective for Other Tests by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Non-Small-Cell
Lung Cancer (NSCLC) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027

Table 20: World Historic Review for Non-Small-Cell Lung Cancer
(NSCLC) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019

Table 21: World 15-Year Perspective for Non-Small-Cell Lung
Cancer (NSCLC) by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 22: World Current & Future Analysis for Small-Cell Lung
Cancer (SCLC) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027

Table 23: World Historic Review for Small-Cell Lung Cancer
(SCLC) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019

Table 24: World 15-Year Perspective for Small-Cell Lung Cancer
(SCLC) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 25: World Current & Future Analysis for Hospital
Laboratories by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027

Table 26: World Historic Review for Hospital Laboratories by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019

Table 27: World 15-Year Perspective for Hospital Laboratories
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Cancer Research
Institutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027

Table 29: World Historic Review for Cancer Research Institutes
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019

Table 30: World 15-Year Perspective for Cancer Research
Institutes by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 31: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027

Table 32: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019

Table 33: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Lung Cancer Stats
US Lung and Bronchus Cancer New Cases by Gender: 2019E
US Lung and Bronchus Cancer Deaths by Gender: 2019E
Incidence Rates* for Lung and Bronchus Cancer by Gender, 2011-2015
Death Rates* for Lung and Bronchus Cancer by Gender in the US,
2012-2016
Incidence Rates for Lung and Bronchus Cancer by Race/Ethnicity,
2011-2015
Reimbursement and Insurance Coverage for Lung Cancer Screening
in the US
CY 2019 Medicare Physician Fee Payment Levels for Low Dose CT
Scan (LDCT) Screening
CY 2019 Hospital Outpatient Prospective Payment System (HOPPS)
Payment Levels for Low Dose CT Scan (LDCT) Screening
Oncimmune?s EarlyCDT Lung to be commercialized in the US by
Biodesix (2019)
Market Analytics
Table 34: USA Current & Future Analysis for Lung Cancer
Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular
Tests, Biopsy and Other Tests - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 35: USA Historic Review for Lung Cancer Diagnostics by
Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy
and Other Tests Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 36: USA 15-Year Perspective for Lung Cancer Diagnostics
by Test - Percentage Breakdown of Value Sales for Imaging
Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests
for the Years 2012, 2020 & 2027

Table 37: USA Current & Future Analysis for Lung Cancer
Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and
Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 38: USA Historic Review for Lung Cancer Diagnostics by
Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung
Cancer (SCLC) Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019

Table 39: USA 15-Year Perspective for Lung Cancer Diagnostics
by Type - Percentage Breakdown of Value Sales for
Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer
(SCLC) for the Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Lung Cancer
Diagnostics by End-Use - Hospital Laboratories, Cancer Research
Institutes and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 41: USA Historic Review for Lung Cancer Diagnostics by
End-Use - Hospital Laboratories, Cancer Research Institutes and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 42: USA 15-Year Perspective for Lung Cancer Diagnostics
by End-Use - Percentage Breakdown of Value Sales for Hospital
Laboratories, Cancer Research Institutes and Other End-Uses for
the Years 2012, 2020 & 2027

CANADA
Table 43: Canada Current & Future Analysis for Lung Cancer
Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular
Tests, Biopsy and Other Tests - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 44: Canada Historic Review for Lung Cancer Diagnostics by
Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy
and Other Tests Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 45: Canada 15-Year Perspective for Lung Cancer
Diagnostics by Test - Percentage Breakdown of Value Sales for
Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and
Other Tests for the Years 2012, 2020 & 2027

Table 46: Canada Current & Future Analysis for Lung Cancer
Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and
Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 47: Canada Historic Review for Lung Cancer Diagnostics by
Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung
Cancer (SCLC) Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019

Table 48: Canada 15-Year Perspective for Lung Cancer
Diagnostics by Type - Percentage Breakdown of Value Sales for
Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer
(SCLC) for the Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Lung Cancer
Diagnostics by End-Use - Hospital Laboratories, Cancer Research
Institutes and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 50: Canada Historic Review for Lung Cancer Diagnostics by
End-Use - Hospital Laboratories, Cancer Research Institutes and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 51: Canada 15-Year Perspective for Lung Cancer
Diagnostics by End-Use - Percentage Breakdown of Value Sales
for Hospital Laboratories, Cancer Research Institutes and Other
End-Uses for the Years 2012, 2020 & 2027

JAPAN
Table 52: Japan Current & Future Analysis for Lung Cancer
Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular
Tests, Biopsy and Other Tests - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 53: Japan Historic Review for Lung Cancer Diagnostics by
Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy
and Other Tests Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 54: Japan 15-Year Perspective for Lung Cancer Diagnostics
by Test - Percentage Breakdown of Value Sales for Imaging
Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests
for the Years 2012, 2020 & 2027

Table 55: Japan Current & Future Analysis for Lung Cancer
Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and
Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 56: Japan Historic Review for Lung Cancer Diagnostics by
Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung
Cancer (SCLC) Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019

Table 57: Japan 15-Year Perspective for Lung Cancer Diagnostics
by Type - Percentage Breakdown of Value Sales for
Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer
(SCLC) for the Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Lung Cancer
Diagnostics by End-Use - Hospital Laboratories, Cancer Research
Institutes and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 59: Japan Historic Review for Lung Cancer Diagnostics by
End-Use - Hospital Laboratories, Cancer Research Institutes and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 60: Japan 15-Year Perspective for Lung Cancer Diagnostics
by End-Use - Percentage Breakdown of Value Sales for Hospital
Laboratories, Cancer Research Institutes and Other End-Uses for
the Years 2012, 2020 & 2027

CHINA
Table 61: China Current & Future Analysis for Lung Cancer
Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular
Tests, Biopsy and Other Tests - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 62: China Historic Review for Lung Cancer Diagnostics by
Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy
and Other Tests Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 63: China 15-Year Perspective for Lung Cancer Diagnostics
by Test - Percentage Breakdown of Value Sales for Imaging
Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests
for the Years 2012, 2020 & 2027

Table 64: China Current & Future Analysis for Lung Cancer
Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and
Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 65: China Historic Review for Lung Cancer Diagnostics by
Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung
Cancer (SCLC) Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019

Table 66: China 15-Year Perspective for Lung Cancer Diagnostics
by Type - Percentage Breakdown of Value Sales for
Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer
(SCLC) for the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Lung Cancer
Diagnostics by End-Use - Hospital Laboratories, Cancer Research
Institutes and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 68: China Historic Review for Lung Cancer Diagnostics by
End-Use - Hospital Laboratories, Cancer Research Institutes and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 69: China 15-Year Perspective for Lung Cancer Diagnostics
by End-Use - Percentage Breakdown of Value Sales for Hospital
Laboratories, Cancer Research Institutes and Other End-Uses for
the Years 2012, 2020 & 2027

EUROPE
Table 70: Europe Current & Future Analysis for Lung Cancer
Diagnostics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 71: Europe Historic Review for Lung Cancer Diagnostics by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019

Table 72: Europe 15-Year Perspective for Lung Cancer
Diagnostics by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Lung Cancer
Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular
Tests, Biopsy and Other Tests - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 74: Europe Historic Review for Lung Cancer Diagnostics by
Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy
and Other Tests Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 75: Europe 15-Year Perspective for Lung Cancer
Diagnostics by Test - Percentage Breakdown of Value Sales for
Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and
Other Tests for the Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Lung Cancer
Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and
Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 77: Europe Historic Review for Lung Cancer Diagnostics by
Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung
Cancer (SCLC) Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019

Table 78: Europe 15-Year Perspective for Lung Cancer
Diagnostics by Type - Percentage Breakdown of Value Sales for
Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer
(SCLC) for the Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Lung Cancer
Diagnostics by End-Use - Hospital Laboratories, Cancer Research
Institutes and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 80: Europe Historic Review for Lung Cancer Diagnostics by
End-Use - Hospital Laboratories, Cancer Research Institutes and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 81: Europe 15-Year Perspective for Lung Cancer
Diagnostics by End-Use - Percentage Breakdown of Value Sales
for Hospital Laboratories, Cancer Research Institutes and Other
End-Uses for the Years 2012, 2020 & 2027

FRANCE
Table 82: France Current & Future Analysis for Lung Cancer
Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular
Tests, Biopsy and Other Tests - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 83: France Historic Review for Lung Cancer Diagnostics by
Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy
and Other Tests Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 84: France 15-Year Perspective for Lung Cancer
Diagnostics by Test - Percentage Breakdown of Value Sales for
Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and
Other Tests for the Years 2012, 2020 & 2027

Table 85: France Current & Future Analysis for Lung Cancer
Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and
Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 86: France Historic Review for Lung Cancer Diagnostics by
Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung
Cancer (SCLC) Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019

Table 87: France 15-Year Perspective for Lung Cancer
Diagnostics by Type - Percentage Breakdown of Value Sales for
Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer
(SCLC) for the Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Lung Cancer
Diagnostics by End-Use - Hospital Laboratories, Cancer Research
Institutes and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 89: France Historic Review for Lung Cancer Diagnostics by
End-Use - Hospital Laboratories, Cancer Research Institutes and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 90: France 15-Year Perspective for Lung Cancer
Diagnostics by End-Use - Percentage Breakdown of Value Sales
for Hospital Laboratories, Cancer Research Institutes and Other
End-Uses for the Years 2012, 2020 & 2027

GERMANY
Table 91: Germany Current & Future Analysis for Lung Cancer
Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular
Tests, Biopsy and Other Tests - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 92: Germany Historic Review for Lung Cancer Diagnostics
by Test - Imaging Tests, Sputum Cytology, Molecular Tests,
Biopsy and Other Tests Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019

Table 93: Germany 15-Year Perspective for Lung Cancer
Diagnostics by Test - Percentage Breakdown of Value Sales for
Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and
Other Tests for the Years 2012, 2020 & 2027

Table 94: Germany Current & Future Analysis for Lung Cancer
Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and
Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 95: Germany Historic Review for Lung Cancer Diagnostics
by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell
Lung Cancer (SCLC) Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019

Table 96: Germany 15-Year Perspective for Lung Cancer
Diagnostics by Type - Percentage Breakdown of Value Sales for
Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer
(SCLC) for the Years 2012, 2020 & 2027

Table 97: Germany Current & Future Analysis for Lung Cancer
Diagnostics by End-Use - Hospital Laboratories, Cancer Research
Institutes and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 98: Germany Historic Review for Lung Cancer Diagnostics
by End-Use - Hospital Laboratories, Cancer Research Institutes
and Other End-Uses Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019

Table 99: Germany 15-Year Perspective for Lung Cancer
Diagnostics by End-Use - Percentage Breakdown of Value Sales
for Hospital Laboratories, Cancer Research Institutes and Other
End-Uses for the Years 2012, 2020 & 2027

ITALY
Table 100: Italy Current & Future Analysis for Lung Cancer
Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular
Tests, Biopsy and Other Tests - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 101: Italy Historic Review for Lung Cancer Diagnostics by
Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy
and Other Tests Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 102: Italy 15-Year Perspective for Lung Cancer
Diagnostics by Test - Percentage Breakdown of Value Sales for
Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and
Other Tests for the Years 2012, 2020 & 2027

Table 103: Italy Current & Future Analysis for Lung Cancer
Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and
Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 104: Italy Historic Review for Lung Cancer Diagnostics by
Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung
Cancer (SCLC) Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019

Table 105: Italy 15-Year Perspective for Lung Cancer
Diagnostics by Type - Percentage Breakdown of Value Sales for
Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer
(SCLC) for the Years 2012, 2020 & 2027

Table 106: Italy Current & Future Analysis for Lung Cancer
Diagnostics by End-Use - Hospital Laboratories, Cancer Research
Institutes and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 107: Italy Historic Review for Lung Cancer Diagnostics by
End-Use - Hospital Laboratories, Cancer Research Institutes and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 108: Italy 15-Year Perspective for Lung Cancer
Diagnostics by End-Use - Percentage Breakdown of Value Sales
for Hospital Laboratories, Cancer Research Institutes and Other
End-Uses for the Years 2012, 2020 & 2027

UNITED KINGDOM
UK Age-standardised Rate (per 100,00) of Lung Cancer Cases by
Gender: 1980-2035P
Market Analytics
Table 109: UK Current & Future Analysis for Lung Cancer
Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular
Tests, Biopsy and Other Tests - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 110: UK Historic Review for Lung Cancer Diagnostics by
Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy
and Other Tests Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 111: UK 15-Year Perspective for Lung Cancer Diagnostics
by Test - Percentage Breakdown of Value Sales for Imaging
Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests
for the Years 2012, 2020 & 2027

Table 112: UK Current & Future Analysis for Lung Cancer
Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and
Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 113: UK Historic Review for Lung Cancer Diagnostics by
Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung
Cancer (SCLC) Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019

Table 114: UK 15-Year Perspective for Lung Cancer Diagnostics
by Type - Percentage Breakdown of Value Sales for
Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer
(SCLC) for the Years 2012, 2020 & 2027

Table 115: UK Current & Future Analysis for Lung Cancer
Diagnostics by End-Use - Hospital Laboratories, Cancer Research
Institutes and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 116: UK Historic Review for Lung Cancer Diagnostics by
End-Use - Hospital Laboratories, Cancer Research Institutes and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 117: UK 15-Year Perspective for Lung Cancer Diagnostics
by End-Use - Percentage Breakdown of Value Sales for Hospital
Laboratories, Cancer Research Institutes and Other End-Uses for
the Years 2012, 2020 & 2027

SPAIN
Table 118: Spain Current & Future Analysis for Lung Cancer
Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular
Tests, Biopsy and Other Tests - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027

Table 119: Spain Historic Review for Lung Cancer Diagnostics by
Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy
and Other Tests Markets - Independent Analysis of Annual Sales

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05834219/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com  
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-global-market-for-lung-cancer-diagnostics-is-projected-to-reach-us3-2-billion-by-2025--301151947.html

SOURCE Reportlinker

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com